The FDA has granted an expedited access pathway designation to Aethlon Medical's Aethlon Hemopurifier. The device is being developed for the removal of highly glycosylated viruses, and it has been studied in hepatitis C patients with end-stage renal disease.
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.